Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Lu, Ruei Min ^a   Chen, Min Shan ^a,b   Chang, De Kuan ^a   Chiu, Chien Yu ^a   Lin, Wei Chuan ^a   Yan, Shin Long ^a   Wang, Yi Ping ^a   Kuo, Yuan Sung ^c   Yeh, Chen Yun ^a   Lo, Albert ^a   Wu, Han Chung ^a,b  

^a INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DOXORUBICIN SERYLMETHIONYLASPARTYLPROLYLPHENYLALANYLLEUCYLPHENYLALANYLGLUTAMINYLLEUCYLLEUCYLGLUTAMINYLLEUCINE CONJUGATE; DOXORUBICIN THREONYLASPARTYLSERYLISOLEUCYLLEUCYLARGINYLSERYLTYROSYLASPARTYLGLYCYLGLYCYLGLYCINE CONJUGATE; LIPOSOME; QUANTUM DOT; SERYLMETHIONYLASPARTYLPROLYLPHENYLALANYLLEUCYLPHENYLALANYLGLUTAMINYLLEUCYLLEUCYLGLUTAMINYLLEUCINE; SULFORHODAMINE B; THREONYLASPARTYLSERYLISOLEUCYLLEUCYLARGINYLSERYLTYROSYLASPARTYLGLYCYLGLYCYLGLYCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER TISSUE; CELL INTERACTION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EARLY DIAGNOSIS; ENDOCYTOSIS; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, SCID; PEPTIDES; POLYETHYLENE GLYCOLS;

EID: 84878929333     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066128     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62: 10-29.
2. DeSantis C, Siegel R, Bandi P, Jemal A, (2011) Breast cancer statistics, 2011. CA: A Cancer Journal for Clinicians 61: 408-418.
3. O'Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, et al. (2012) Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer. The Oncologist 17: 476-484.
4. Cobleigh MA, (2011) Other Options in the Treatment of Advanced Breast Cancer. Seminars in Oncology 38Supplement 2: S11-S16.
5. Heldin CH, Rubin K, Pietras K, Ostman A, (2004) High interstitial fluid pressure- an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
6. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418-429.
7. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, et al. (1998) Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58: 1195-1201.
8. Chang DK, Lin CT, Wu CH, Wu HC, (2009) A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 4: e4171.
9. Hambley TW, Hait WN, (2009) Is anticancer drug development heading in the right direction? Cancer Res 69: 1259-1262.
10. Minchinton AI, Tannock IF, (2006) Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
11. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
12. Davis ME, Chen Z, Shin DM, (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
13. Farokhzad OC, Langer R, (2009) Impact of nanotechnology on drug delivery. ACS Nano 3: 16-20.
14. Shi J, Votruba AR, Farokhzad OC, Langer R, (2010) Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications. Nano Letters 10: 3223-3230.
15. Matsumura Y, Maeda H, (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392.
16. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release 65: 271-284.
17. Wagner V, Dullaart A, Bock A-K, Zweck A, (2006) The emerging nanomedicine landscape. Nat Biotech 24: 1211-1217.
18. Slingerland M, Guchelaar H-J, Gelderblom H, (2012) Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discovery Today 17: 160-166.
19. Iber FL, Nassau K, Plough IC, Berger FM, Meroney WH, et al. (1958) The use of radioiodinated albumin in metabolic studies; the effects of the level of dietary protein and L-triiodothyroinine on the catabolism of radioiodinated human serum albumin. J Clin Invest 37: 1442-1452.
20. Kratz F, (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. Journal of Controlled Release 132: 171-183.
21. Kohlschütter J, Michelfelder S, Trepel M, (2008) Drug delivery in acute myeloid leukemia. Expert Opinion on Drug Delivery 5: 653-663.
22. Torchilin V, (2008) Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 5: 1003-1025.
23. Wu HC, Chang DK, (2010) Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. J Oncol 2010: 723798.
24. Svensen N, Walton JGA, Bradley M, (2012) Peptides for cell-selective drug delivery. Trends in pharmacological sciences 33: 186-192.
25. Chang DK, Chiu CY, Kuo SY, Lin WC, Lo A, et al. (2009) Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem 284: 12905-12916.
26. Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, et al. (2011) The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 10: 389-397.
27. Cho HJ, Yoon IS, Yoon HY, Koo H, Jin YJ, et al. (2012) Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 33: 1190-1200.
28. Park J-H, von Maltzahn G, Zhang L, Derfus AM, Simberg D, et al. (2009) Systematic Surface Engineering of Magnetic Nanoworms for In vivo Tumor Targeting. Small 5: 694-700.
29. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, et al. (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8: 1172-1181.
30. Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, et al. (2005) Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting Conjugate. 1. Gram-Scale Production and Purification. Biotechnology Progress 21: 205-220.
31. Wang T, D'Souza GGM, Bedi D, Fagbohun OA, Potturi LP, et al. (2010) Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine 5: 563-574.
32. Shadidi M, Sioud M, (2003) Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J 17: 256-258.
33. Lee CM, Iorno N, Sierro F, Christ D, (2007) Selection of human antibody fragments by phage display. Nat Protoc 2: 3001-3008.
34. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC, (2007) Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67: 10958-10965.
35. Lu R-M, Chang Y-L, Chen M-S, Wu H-C, (2011) Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32: 3265-3274.
36. Lee TY, Wu HC, Tseng YL, Lin CT, (2004) A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res 64: 8002-8008.
37. Schagger H, (2006) Tricine-SDS-PAGE. Nat Protoc 1: 16-22.
38. Cai W, Chen X, (2008) Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc 3: 89-96.
39. Lo A, Lin CT, Wu HC, (2008) Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 7: 579-589.
40. Barenholz Y, (2012) Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release 160: 117-134.
41. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, et al. (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440-449.
42. Wu H, Chang D, Huang C, (2006) Targeted-therapy for cancer. J Cancer Mol 2: 57-66.
43. Carmeliet P, Jain RK, (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
44. Cheng WW, Allen TM, (2010) The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv 7: 461-478.
45. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, et al. (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750-4755.
46. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJP, et al. (2011) Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors. Cancer Research 71: 2250-2259.
47. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.